Surgery to treat bleeding under the retina in wet macular degeneration
Part of Eyes & vision clinical trials.
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older.
- Your eye has bleeding under the retina involving the center of the vision (the fovea) and it is at least a certain size on imaging.
- That bleeding has been present for 15 days or less (or they can’t confirm it’s older).
- The bleeding is thick enough on a scan (at least 125 microns at the center).
- Your current vision is between “counting fingers” and a specific ETDRS score range.
- You can attend follow-up visits for the full study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This study tests a new investigational drug called BETA-TT8 for people with wet age-related macular degeneration (wet AMD) who have already been treated with standard therapy (aflibercept). The goal is to see if this new treatment is safe and effective in improving vision.
Hear when a new Eye Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.